Companies like Compremium, Cutiss, Comphya and Novostia are currently testing their groundbreaking technologies in human trials.
Compremium’s diagnostic innovations
Compremium is developing non-invasive, portable diagnostic solutions for pressure-related conditions in the human body. Utilizing ultrasound-based technology, Compremium’s pressure sensor, employing the pressure-related ultrasound – PrUS – approach, demonstrated promising results in a recent pediatric study. This technology could revolutionize the management of soft tissue swelling after limb fractures, mitigating the risk of acute compartment syndrome (ACS). Further trials are anticipated to validate its efficacy in clinical settings. The Bern-based innovator has delivered its pioneering Compartmental Compressibility Monitoring System to NASA, a significant leap in ensuring astronaut health for deep space missions.
Cutiss’ skin regenerative advances
Cutiss, specializing in skin regenerative medicine and tissue engineering based on technology developed at the CSEM in Neuchâtel, has completed recruitment for its denovoSkin phase II trial. This study, involving Swiss, Italian, and Dutch hospitals, focuses on the safety and efficacy of denovoSkin, a personalized, bio-engineered skin substitute, in reconstructive surgery. With a 3-year follow-up period, initial results could emerge within the next year. Additionally, denovoSkin is transitioning towards phase III trials for treating burns, having received Orphan Drug Designation from various regulatory bodies.
Comphya’s erectile dysfunction treatment
EPFL spin-off Comphya is addressing erectile dysfunction with its patented neuro-stimulator, CaverSTIM. Designed for patients non-responsive to oral therapy, this implanted device selectively activates the nerve to trigger penile erection. The first successful implantations have been carried out in spinal cord injury individuals in Brazil, with more surgeries underway.
Novostia’s artificial heart valve
Lausanne-based Novostia is developing an artificial heart valve, TRIFLO, made from high-performance biocompatible material. This innovative valve ensures optimal blood flow and clot prevention. Novostia recently received approval for a First-in-Human trial of its aortic heart valve prosthesis in Lithuania. The TRIFLO project has garnered support from EU and Swiss funding bodies, reflecting its potential in improving heart valve replacement therapies.
These medical technology start-ups and innovations from Western Switzerland are at the forefront of medical innovation, with human trials set to validate their transformative technologies. Their advancements hold the promise of significantly improving patient care and outcomes in various medical fields.
